New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most

There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.

Related posts

U.S. to Review Social Media Posts of Student and Scholar Visa Applicants

Regulators Approve Lenacapavir for H.I.V. Prevention

When Humans Learned to Live Everywhere